Introduction & objectives
Publication about dose recommendations for N,N-dimethyltryptamine (DMT), a psychedelic compound, that, together with other serotonergic psychedelics such as LSD and psilocybin, is believed to have potential as as a therapeutic treatment option in depression and a number of other psychiatric conditions.
This publication provides a starting point for designing DMT infusion studies, targeting a specific psychedelic intensity score, with dose recommendations based on a target response, indicating that no single dose is likely to lead to a large proportion of the population within target. Furthermore, differences between the continuous variable model and the bounded integer model which may impact dose selection are demonstrated.
Study findings context & significance
The results show that a bolus dose of 14-16 mg DMT fumarate followed by an infusion rate of 1.2-1.4 mg/min are expected to achieve intensity ratings between 7 and 9 (possible range = 0–10).
In recent years, the need for new treatments in psychiatric disorders, such as depression and anxiety, has led to an increase in research with different psychedelic compounds. The effects of these compounds naturally include a subjective component related to the psychedelic experience and it has been hypothesized that this component is closely related to therapeutic effect. Studies like these contribute to advancing understanding around, and the use of new treatments potential.